GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It ...

Outside of the U.S., Arexvy is now launched in 36 markets ... European countries and a national immunization program in Australia. Shingrix is now launched in 52 countries, and the average ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Explore the key data from our strong 2024 performance. More information for media ...

GSK’s global performance showed strength across key markets. Sales in the United States reached £16.4 billion, up 6% at ...

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

Vaccines sales declined 3% in 2024, reflecting pressures on Arexvy and Shingrix in the U.S. However, Arexvy remains the market leader, and international uptake is gaining momentum. Emily Field ...

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s for whom it is approved.

Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel ...

But new research from Tourism Australia crowns a beach in Tasmania as the country’s best for 2025. The accolade for Australia’s best beach has been awarded to a 10km stretch of coastline in ...

After a blockbuster burst onto the market last year, sales of the RSV vaccine Arexvy nosedived this season. In a similar pattern already seen in the third quarter, Arexvy sales in the fourth ...